Viking Therapeutics Inc (1VT F) stock market data APIs
€29.4869
-1.04(-3.5%)
as of October 17, 2025
Try our APIs with
free plan!
Viking Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
Prev. Close
29.4869
Open
28.4503
High
29.4869
Low
26.0538
52 wk Range
16.4-83.5
Market Cap
3 319 M
Shares Outstanding
112 M
Beta
0.635
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Viking Therapeutics Inc data using free add-ons & libraries
Get Viking Therapeutics Inc Fundamental Data
Viking Therapeutics Inc Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-10-22
- EPS/Forecast: -0.67
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Viking Therapeutics Inc News
New
Viking Therapeutics (VKTX) Receives a Buy from Oppenheimer
Viking Therapeutics, Inc. (NASDAQ:VKTX) is one of the best healthcare stocks with the highest upside. Viking Therapeutics, Inc. (NASDAQ:VKTX) received a Buy rating from Oppenheimer’s Jay Olson on Oc...
Viking Therapeutics, Inc. (VKTX) Stock Dips While Market Gains: Key Facts
In the latest close session, Viking Therapeutics, Inc. (VKTX) was down 3.44% at $33.54. This move lagged the S&P 500's daily gain of 0.53%. Meanwhile, the Dow experienced a rise of 0.52%, and the tech...
Pre-Q3 Earnings: Is Viking Therapeutics Stock a Portfolio Must-Have?
Viking Therapeutics VKTX is set to report third-quarter 2025 earnings on Oct. 22, after market close. Since the company lacks a marketed drug in its portfolio, no revenues are expected to be recorded...
The Zacks Analyst Blog Highlights Eli Lilly, Novo Nordisk, Amgen and Viking Therapeutics
For Immediate Release Chicago, IL – October 17, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news an...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
